Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Other Non-Current Assets: 2019-2024

Historic Other Non-Current Assets for BridgeBio Pharma (BBIO) over the last 6 years, with Dec 2024 value amounting to $18.2 million.

  • BridgeBio Pharma's Other Non-Current Assets rose 25.78% to $25.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.5 million, marking a year-over-year increase of 25.78%. This contributed to the annual value of $18.2 million for FY2024, which is 19.58% down from last year.
  • As of FY2024, BridgeBio Pharma's Other Non-Current Assets stood at $18.2 million, which was down 19.58% from $22.6 million recorded in FY2023.
  • In the past 5 years, BridgeBio Pharma's Other Non-Current Assets ranged from a high of $33.0 million in FY2021 and a low of $18.2 million during FY2024.
  • Over the past 3 years, BridgeBio Pharma's median Other Non-Current Assets value was $20.2 million (recorded in 2022), while the average stood at $20.3 million.
  • In the last 5 years, BridgeBio Pharma's Other Non-Current Assets surged by 38.01% in 2021 and then crashed by 38.77% in 2022.
  • Yearly analysis of 5 years shows BridgeBio Pharma's Other Non-Current Assets stood at $23.9 million in 2020, then surged by 38.01% to $33.0 million in 2021, then tumbled by 38.77% to $20.2 million in 2022, then increased by 11.87% to $22.6 million in 2023, then dropped by 19.58% to $18.2 million in 2024.